Trials / Unknown
UnknownNCT05813379
Mesenchymal Stem Cells Derived Exosomes in Skin Rejuvenation
Application of Mesenchymal Stem Cells Derived Exosomes in Skin Rejuvenation
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Isfahan University of Medical Sciences · Academic / Other
- Sex
- Female
- Age
- 35 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Aging is a natural and complex process. The effect of environmental factors, genetics on the body eventually leads to damage in different ways. Exosomes are present in almost all body fluids, such as synovial fluid and blood. Exosomes and microvesicles are very efficient mediators of cell-to-cell communication by transferring their specific cargo to recipient cells; for example, exosomes are involved in the delivery of genetic materials, causing epigenetic modifications in the target cells .The applications of MSC-derived exosomes have more effect in cutaneous regeneration by collagen stimulation.The basic biology of exosomes indicates that MSC-exosomes may contain MSC-specific components to exert specific effects on recipient cells, which are somewhat equivalent to the regenerative effects of MSCs. This study aims to slow down the aging process of the skin by using exosome.
Detailed description
Skin aging is a complex biological process that can be classified into extrinsic or intrinsic aging. Intrinsic aging is an intrinsic degradation process that is caused by a decrease in the proliferation capacity leading to cell senescence. Angiogenesis is essential in various physiological processes, including wound healing and skin tissue regeneration. Literature reviews show that exosomes derived from human umbilical cord blood mesenchymal stem cells can cause Collagen stimulation and reduction of oxidative stress, WNT/βcatenin pathway signaling in the initial stages of causes the regeneration of skin damage . This study aims to slow down the aging process of the skin by using exosome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | exosime injection | Treatment- exosome injection |
Timeline
- Start date
- 2022-02-01
- Primary completion
- 2023-07-29
- Completion
- 2023-08-30
- First posted
- 2023-04-14
- Last updated
- 2023-04-14
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT05813379. Inclusion in this directory is not an endorsement.